The inflammatory cytokine interleukin-23 is elevated in lung cancer, particularly small cell type

Caner Cam; Bulent Karagoz; Tuba Muftuoglu; Oguz Bigi; Levent Emirzeoglu; Serkan Celik; Alpaslan Ozgun; Tolga Tuncel; Cihan Top

doi:10.5114/wo.2016.61562

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2016
vol. 20

Send email

Copy url:

abstract:

Original paper

The inflammatory cytokine interleukin-23 is elevated in lung cancer, particularly small cell type

Caner Cam

,

Bulent Karagoz

,

Tuba Muftuoglu

,

Oguz Bigi

,

Levent Emirzeoglu

,

Serkan Celik

,

Alpaslan Ozgun

,

Tolga Tuncel

,

Cihan Top

Contemp Oncol (Pozn) 2016; 20 (3): 215-219

DOI: https://doi.org/10.5114/wo.2016.61562

Online publish date: 2016/08/04

View full text Get citation

PlumX metrics:

Aim of the study: Interleukin (IL)-17 and IL-23 play roles in inflammation and autoimmunity. The function of the IL-17/IL-23 pathway has not been completely evaluated in cancer patients. We aimed to investigate serum IL-17 and IL-23 levels and their relationship with clinicopathological and biochemical parameters in lung cancer patients.

Material and methods: Forty-five lung cancer patients and 46 healthy volunteers were included in the study. IL-17 and IL-23 measurements were made with the ELISA method. The ages of patients (53–84 years) and healthy subjects (42–82 years) were similar.

Results: Serum IL-23 levels were higher in lung cancer patients than in healthy subjects (491.27 ±1263.38 pg/ml vs. 240.51 ±233.18 pg/ml; p = 0.032). IL-23 values were higher in small cell lung cancer (SCLC) patients than in non-small cell lung cancer (NSCLC) patients (1325.30 ±2478.06 pg/ml vs. 229.15 ±103.22 pg/ml; p = 0.043). Serum IL-17 levels were lower in the patients, but the difference was not statistically significant (135.94 ±52.36 pg/ml vs. 171.33 ±133.51 pg/ml; p = 0.124). Presence of comorbid disease (diabetes mellitus, hypertension or chronic obstructive lung disease) did not have any effect on the levels of IL-17 or IL-23. Erythrocyte sedimentation rate values were positively correlated with cytokine levels, but serum albumin levels were negatively correlated.

Conclusions: Serum IL-23 levels are elevated in lung cancer patients, particularly those with SCLC. IL-17 and IL-23 values are correlated with inflammatory markers in the patients.

keywords:

The inflammatory cytokine interleukin-23 is elevated in lung cancer, particularly small cell type

Caner Cam , Bulent Karagoz , Tuba Muftuoglu , Oguz Bigi , Levent Emirzeoglu , Serkan Celik , Alpaslan Ozgun , Tolga Tuncel , Cihan Top

IL-17, IL-23, lung cancer, Th17 cells

Caner Cam

,

Bulent Karagoz

,

Tuba Muftuoglu

,

Oguz Bigi

,

Levent Emirzeoglu

,

Serkan Celik

,

Alpaslan Ozgun

,

Tolga Tuncel

,

Cihan Top